Mineralys Therapeutics reports Phase 3 Transform-HTN extension data for lorundrostat

Mineralys Therapeutics announced Phase 3 Transform-HTN extension data for lorundrostat showing a sustained 17.8 mmHg systolic blood pressure reduction at week 48, with 56% of patients achieving BP below 130 mmHg.

Detected & updated continuously · Source: Nebula